Organization

Ensures corporate ethics and statutes are complied with in accordance with the JPMA Member Company Charter and Compliance Program Guidelines.

Coordinates with organizations and related JPMA committees to ensure compliance with the Ethical Drug Promotion Code.

Optimizes dissemination of information on ethical drugs and reviews member companies' product information brochures, advertisements, and related publishes information.

Aims for accoutable and efficient distribution of drug products and related organizations and governmental bodies. Undertakes surveys and studies on drug product distribution for policy and strategy proposal.

Promotes appropriate measures for research and development of new drugs, post-marketing safety measures, and appropriate use of drugs. Proposes policies and strategies based on research on technology, regulatory science and regulation.

Joins the International Conference on Hamonization of Technical Requirements for Registration of Pharmaceuticals for Human Use(ICH),in which the regulatory authorities and pharmaceutical industry of Europe, Japan and the United States bring together to develop tripartite harmonized guidelines. The Project promotes better understanding of draft and finalized tripartite guidelines through regular capacity building activities, such as workshops, training courses and seminars that enable people to improve their skills and knowledge.

Conducts surveys and studies on good manufacturing practice(GMP), and pharmaceutical manufacturing technology with subjects related to their physical properties. Establishes and promotes measures to improve reliability and quality of pharmaceutical products. Develops guidelines on quality topics within the framework of trilateral harmonization(Japan, US, and EU) in collaboration with ICH Project Committee.

Presents recommendations to governmental bodies on biopharmaceutical-related policies concerning the infrastructure development for promoting R&D of biotechnology-based drugs. Investigates technical issues in R&D, manufacturing, post-marketing surveillance, and recommends the relevant ministries/agencies on improvements.

Investigates problems in implementing the Pharmaceutical Affairs Act, the approval process of drugs, and safety measures in pharmaceutical regulations, and recommends the pharmaceutical agencies on policies regarding to effective corporate activities and swift drug approval etc. from stand points of R&D-based pharmaceutical companies.

Coodinates with relevant gorvernmental bodies and other organizations to make Japan an intellectual property-based nation. Proposes new policies and strategies to extablish a virtual cycle of creation, protection, and utilization of intellectual property worldwide in Life Science.

Improves the infrastructure for medicinal research including introduction of new technology. Promotes industry-academia-government coalitions to stimulate transfer technology from academia to the pharmaceutical industry and train Professionals.

Attends international meetings and conferences with IFPMA, other associations, and international organizations, to clarify issues which member companies have and propose policies. Supports promoting GMP for better quality assuarance in Asian countries.

Defines best practice models for global envaironment preservation and occupational safety and health management. Supports member companies' measures on the environment and safety. Prepares and publishes JPMA Environmental Reports annually, and conducts dialogues with outside organizations.

Develops activities to improve public recognition and understanding of medicines and the pharmaceutical industry. Takes action to facilitate adoption and implementation of JPMA proposals and policies.

Collects domestic and overseas information and takes appropriate measures on issues related to importation, exportation, and customs duties of medicines and intermediate medicinal products in coalition with related organizations. Takes prompt action to address issues related to the trade of medicines, drug substances, bulk powder, and raw materials.

Investigates and advises on apropriate ways to provide the public with drug information and on how product information departments should operate, to gain more reliability and recognitions, thus contributing to Patient-oriented Health Care.

Exchanges of information positively with the patient groups, executes the dissemination of information and the measures that stands in patient’s aspect and strive to build relationships with the patient organizations.

Conducts research on medium to long term strategic policies and related topics for the development of the pharmaceutical industry and its contribution to society.

Publishes and distributes the results of activities of JPMA committees and surveys. Organizes various seminars, meetings, and lectures on behalf of JPMA committees.